Key facts
- Notable investors include Sichuan Venture Capital, Guanghua Kaiyuan Capital, Ming Capital, Neowing Capital, Wuhan East Lake High Technology Group Company — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Gene Vector
- ·The full record, as it builds
Funding rounds
No funding rounds for Gene Vector are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gene Vector
Developer of novel adeno-associate virus (AAV) gene therapy drugs designed for the medical field. The company focuses on gene therapy for major diseases such as hereditary diseases, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases, enabling a complete AAV new drug research and development technology chain to deliver novel biotherapy solutions.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2017
- Website
- jwksw.com/
- Ownership
- Privately Held (backing)
Gene Vector doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gene Vector shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gene Vector in its N-PORT filings yet. We sweep new filings monthly.